Evidence map›Paper›PMID 24853183›Full record

ArticleBritish journal of cancer2014

Multi-colour FISH in oesophageal adenocarcinoma-predictors of prognosis independent of stage and grade.

C-I Geppert, P Rümmele, M Sarbia, R Langer, M Feith, L Morrison, E Pestova, R Schneider-Stock, A Hartmann, T T Rau

Open access · hybridAbstract read
In one paragraph

Article in British journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Somatic deletion ofJournal of clinical pathology · 2020
    Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 3 countries.

C-I Geppert1] Department of Pathology, Friedrich-Alexander Universität Erlangen-Nürnberg, Krankenhausstrasse 8/10, 91054 Erlangen, Germany [2] Comprehensive Cancer Center Erlangen-European Metropolitan Region Nuremberg 91054 Erlangen, Germany.
P RümmeleDepartment of Pathology, University Hospital Regensburg, 93053 Regensburg, Germany.
M SarbiaDepartment of Pathology and Cytology, 80992 Munich, Germany.
R LangerDepartment of Pathology, University Bern, CH 3010 Bern, Switzerland.
M FeithDepartment of Surgery, Klinikum Rechts der Isar, Technical University Munich, 81675 Munich, Germany.
L MorrisonVentana Medical Systems, Inc., Oro Valley, AZ 85755, USA.
E PestovaAbbott Molecular, Des Plaines, IL 60018, USA.
R Schneider-Stock1] Department of Pathology, Friedrich-Alexander Universität Erlangen-Nürnberg, Krankenhausstrasse 8/10, 91054 Erlangen, Germany [2] Comprehensive Cancer Center Erlangen-European Metropolitan Region Nuremberg 91054 Erlangen, Germany.
A Hartmann1] Department of Pathology, Friedrich-Alexander Universität Erlangen-Nürnberg, Krankenhausstrasse 8/10, 91054 Erlangen, Germany [2] Comprehensive Cancer Center Erlangen-European Metropolitan Region Nuremberg 91054 Erlangen, Germany.
T T Rau1] Department of Pathology, Friedrich-Alexander Universität Erlangen-Nürnberg, Krankenhausstrasse 8/10, 91054 Erlangen, Germany [2] Comprehensive Cancer Center Erlangen-European Metropolitan Region Nuremberg 91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen · DEAbbott (United States) · USFriedrich-Alexander-Universität Erlangen-Nürnberg · DEKlinikum rechts der Isar · DEUniversity Hospital Regensburg · DEUniversity of Bern · CHVentana Research Corporation (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOesophageal adenocarcinoma or Barrett's adenocarcinoma (EAC) is increasing in incidence and stratification of prognosis might improve disease management. Multi-colour fluorescence in situ hybridisation (FISH) investigating ERBB2, MYC, CDKN2A and ZNF217 has recently shown promising results for the diagnosis of dysplasia and cancer using cytological samples.

methodsTo identify markers of prognosis we targeted four selected gene loci using multi-colour FISH applied to a tissue microarray containing 130 EAC samples. Prognostic predictors (P1, P2, P3) based on genomic copy numbers of the four loci were statistically assessed to stratify patients according to overall survival in combination with clinical data.

resultsThe best stratification into favourable and unfavourable prognoses was shown by P1, percentage of cells with less than two ZNF217 signals; P2, percentage of cells with fewer ERBB2- than ZNF217 signals; and P3, overall ratio of ERBB2-/ZNF217 signals. Median survival times for P1 were 32 vs 73 months, 28 vs 73 months for P2; and 27 vs 65 months for P3. Regarding each tumour grade P2 subdivided patients into distinct prognostic groups independently within each grade, with different median survival times of at least 35 months.

conclusionsCell signal number of the ERBB2 and ZNF217 loci showed independence from tumour stage and differentiation grade. The prognostic value of multi-colour FISH-assays is applicable to EAC and is superior to single markers.

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overBarrett EsophagusBiomarkers, TumorCyclin-Dependent Kinase Inhibitor p16DNA, NeoplasmErb-b2 Receptor Tyrosine KinasesEsophageal NeoplasmsFemaleGene DosageHumansIn Situ Hybridization, FluorescenceMaleMiddle AgedBiomarkers, TumorCyclin-Dependent Kinase Inhibitor p16DNA, NeoplasmERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesMYC protein, humanProto-Oncogene Proteins c-mycTrans-ActivatorsZNF217 protein, human

Identifiers

PMID24853183
PMCPMC4056055
OpenAlexW2041525337

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.